Brainsway Gets FDA Approval for Multi-Center Bipolar Trial
Brainsway Ltd. (BRIN) said it received approval from the U.S. Food and Drug Administration to begin a multi-center trial to test the efficacy of its Deep TMS device for the treatment of bipolar disorder, according to a filing today with the Tel Aviv Stock Exchange.
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at firstname.lastname@example.org
To contact the editor responsible for this story: Alisa Odenheimer at email@example.com
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.